Randomized Trialhigh evidence

Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial.

Lancet (London, England)·November 9, 2026·PMID 43003106

Why it matters

Cardiovascular safety is a critical regulatory and clinical concern for novel incretin-based therapies. This trial provides reassurance that survodutide does not increase major adverse cardiovascular events in a high-risk obese population, supporting its potential use in cardiometabolic management.

Infographic summary of Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial.
Visual abstract · MedLit

The papers that matter, first.

MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.

§

MedLit · Evidence, Distilled